HIV Antibody VRC01 Shows Promise in Early Trials

This article originally appeared here.
Share this content:
HIV Antibody VRC01 Shows Promise in Early Trials
HIV Antibody VRC01 Shows Promise in Early Trials

THURSDAY, Nov. 10, 2016 (HealthDay News) -- Antibodies may keep the HIV virus in check and one day allow patients to stop taking antiretroviral drugs, according to research published online Nov. 9 in the New England Journal of Medicine.

For one study (National Institutes of Health), patients were given infusions of VRC01 before they stopped antiretroviral therapy. Additional infusions were given at two and four weeks after halting antiretroviral therapy and then monthly for up to six months. In a second trial (AIDS Clinical Trials Group), researchers at the University of Pennsylvania and the University of Alabama gave patients VRC01 infusions one week before stopping antiretroviral therapy and then every three weeks for up to three doses.

After regular intravenous infusions of VRC01, participants in the U.S. National Institutes of Health and the AIDS Clinical Trials Group studies experienced viral rebound at an average of 39 and 28 days, respectively, after antiretroviral therapy was stopped.

The next phase is to infuse two or three antibodies intermittently, and see if antiretroviral drugs can be withdrawn permanently, coauthor Anthony Fauci, M.D., director of the U.S. National Institute of Allergy and Infectious Diseases, told HealthDay. If this approach is successful, the possible benefit to patients is that they could stop taking antiretroviral drugs altogether, he said.

Abstract
Full Text
Perspective

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

GDM Found to Increase Risk for Postpartum Depression

GDM Found to Increase Risk for Postpartum Depression

Researchers find odds up even more if woman has suffered an earlier bout of depression

Cervical Cancer Mortality Higher Among Older, Black Women

Cervical Cancer Mortality Higher Among Older, Black Women

Rates rose when latest study excluded women who'd already undergone hysterectomy

Many Advanced NSCLC Patients Not Getting Helpful Treatment

Many Advanced NSCLC Patients Not Getting Helpful Treatment

Study found 21 percent went without therapy, even though it could boost survival

is free, fast, and customized just for you!

Already a member?

Sign In Now »